Search
Antihemophilic factor, human recombinant
go.drugbank.com/drugs/DB00025ApprovedInvestigationalHuman recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
Mixtures: FANHDI 250 U.I., HAEMATE PCategories: Hemophilia AIopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast ActivityProducts: Isovue 370 Inj 76%, Isovue 250Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Categories: MATE 2 Inhibitors, MATE 1 InhibitorsProducts: RANEXICOR ® 500, RANEXICOR ® 1000Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigationalTamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamineDorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigationalDorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and … [L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.
Mixtures: DORZOLOL® UD, Cosopt 20 mg/ml + 5 mg/ml AugentropfenCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingOxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigationalefficacy since initial FDA approval in 1975. … Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat, 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolateCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of … [A232920] β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately
Mixtures: ZAVİCEFTA 2 G/0.5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 10 ADET, CEFAZIME FOR INJECTION 1 g/vialCategories: Heterocyclic Compounds, 2-RingRasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain. … The cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.
Products: FASTURTEC 7,5 MG/5 ML INFIZYONLUK COZELTI ICIN TOZ VE COZUCU, 1ADET, FASTURTEC®1.5 MG / MLPeramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalfor no more than two days. … The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic
Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet)Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … [A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for
Mixtures: Betamethasone Dipropionate 0.05% / Minoxidil 5% / Niacinamide 2% / Pentoxifylline 0.5%Categories: Phosphodiesterase 5 Inhibitors, Heterocyclic Compounds, 2-Ring